STOCK TITAN
  1. Home
  2. Sec-filings
  3. TNXP
  4. [8-K] Tonix Pharmaceuticals Holding Corp. Reports Material Event

Tonix Pharma (TNXP) CEO takes on interim chief medical role

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Tonix Pharmaceuticals Holding Corp. (TNXP) reported that on August 18, 2026, its Board of Directors appointed Dr. Seth Lederman, the company’s President, Chief Executive Officer and Chairman of the Board, as Interim Chief Medical Officer. Dr. Lederman, age 69, has held his existing leadership roles since October 2011 and will continue to serve in all of these positions concurrently.

The company states there are no arrangements or understandings with any other person related to his appointment, and no family relationships between Dr. Lederman and any director or executive officer. Tonix publicly announced his appointment as Interim Chief Medical Officer on the same date.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Appointment date August 18, 2026 Date Dr. Seth Lederman was appointed Interim Chief Medical Officer
Executive age 69 Age of Dr. Seth Lederman at the time of appointment
Leadership tenure start October 2011 Start of Dr. Lederman’s service as President, CEO and Chairman of the Board
Interim Chief Medical Officer medical
"appointed Dr. Seth Lederman ... as the Company’s Interim Chief Medical Officer"
emerging growth company regulatory
"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ... Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Exchange Act regulatory
"pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)"
A federal law that sets rules for trading securities on public exchanges, requiring companies and market participants to register, disclose regular financial information, and follow standards that promote honest, orderly markets. For investors, it matters because it creates transparency and legal protections—like stopping insider trading and ensuring timely company disclosures—so you can evaluate risks and rely on consistent rules much as players rely on a referee to keep a game fair.

FAQ

What executive change did Tonix Pharmaceuticals (TNXP) announce on August 18, 2026?
Tonix Pharmaceuticals appointed Dr. Seth Lederman as Interim Chief Medical Officer on August 18, 2026. He will hold this role in addition to serving as President, Chief Executive Officer and Chairman of the Board.

Does Dr. Seth Lederman keep his other roles at Tonix Pharmaceuticals (TNXP)?
Yes. Dr. Lederman will continue as President, Chief Executive Officer and Chairman of the Board while also serving as Interim Chief Medical Officer. He has held these leadership roles since October 2011.

How old is Dr. Seth Lederman, the new Interim Chief Medical Officer of TNXP?
Dr. Seth Lederman is 69 years old. He has been leading Tonix Pharmaceuticals as President, Chief Executive Officer and Chairman of the Board since October 2011 and now adds the Interim Chief Medical Officer role.

When did Tonix Pharmaceuticals (TNXP) publicly announce Dr. Lederman’s new role?
Tonix announced Dr. Lederman’s appointment as Interim Chief Medical Officer on August 18, 2026. This public announcement occurred on the same date the Board approved his appointment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false 0001430306 0001430306 2026-08-18 2026-08-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (date of earliest event reported): August 18, 2026

 

TONIX PHARMACEUTICALS HOLDING CORP.

(Exact name of registrant as specified in its charter)

 

Nevada   001-36019   26-1434750

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

200 Connell Drive, Berkeley Heights, New Jersey 07922

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (862) 799-8599

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   TNXP   The NASDAQ Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Interim Chief Medical Officer

 

On August 18, 2026, the Board of Directors of Tonix Pharmaceuticals Holding Corp. (the “Company”) appointed Dr. Seth Lederman, the Company’s President and Chief Executive Officer, as the Company’s Interim Chief Medical Officer.

 

Dr. Lederman, age 69, has been the Company’s President, Chief Executive Officer and Chairman of the Board since October 2011, and will continue to serve in these roles.

 

There are no arrangements or understandings between Dr. Lederman and any other person pursuant to which Dr. Lederman was appointed Interim Chief Medical Officer. There are no family relationships between Dr. Lederman and any director or executive officer of the Company.

 

Item 8.01 Other Events.

 

On August 18, 2026, the Company announced the appointment of Dr. Lederman to Interim Chief Medical Officer of the Company.

 

 
 

 

SIGNATURE

 

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  TONIX PHARMACEUTICALS HOLDING CORP.
   
Date: August 18, 2026 By: /s/ Bradley Saenger                
    Bradley Saenger
    Chief Financial Officer

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents